ClinicalTrialsFinder
RecruitingPhase 1NCT05389319

A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

A Phase I/IIa, Dose-finding Study to Assess the Safety and Immunogenicity of an Orf Virus-based COVID-19 Vaccine Booster (Prime-2-CoV_Beta) in Healthy Adults

Sponsor

University Hospital Tuebingen

Enrollment

96 participants

Start Date

Jun 24, 2022

Study Type

INTERVENTIONAL

Conditions

COVID-19

Summary

This is an open-label, first-in-human, dose-finding study to evaluate the safety and immunogenicity of a booster vaccination of Prime-2-CoV\_Beta in healthy participants.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Prime-2-CoV_Beta for people with covid-19. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPrime-2-CoV_Beta

1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1

Locations(2)

University Hospital Tübingen, Institute of Tropical Medicine

Tübingen, Baden-Wurttemberg, Germany

Bernhard-Nocht-Institut für Tropenmedizin

Hamburg, Free and Hanseatic City of Hamburg, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05389319

Related Trials

Patient-Centered Practical Vaccine Talk For Busy Clinicians

NCT076517611 location

Serological and PCR Testing for COVID-19

NCT044040621 location

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

NCT076551801 location

Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection

NCT052421591 location

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT075363086 locations